Who Owns BlossomHill Therapeutics Stock?
NASDAQ: BLSMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 30.62%
- Held by insiders
- 12.71%
- Institutional holders
- 10
- Institutions 30.6%
- Insiders 12.7%
- Public and other 56.7%
Who owns BlossomHill Therapeutics stock?
Institutional investors own about 30.6% of BlossomHill Therapeutics's shares, spread across 10 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 12.71% of BLSM.
Summary generated from market data by MetaCap's automated system. Methodology
Top mutual fund and ETF holders of BLSM
| Fund | Shares | % Held |
|---|---|---|
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 347.40K | 1.09% |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 133.40K | 0.42% |
| Voya Investors Trust-VY(R) JPMorgan Small Cap Core Equity Portfolio | 11.51K | 0.04% |
Frequently asked questions
What percentage of BlossomHill Therapeutics is owned by institutions?
Institutions own about 30.6% of BLSM shares and 35.1% of the public float.
How much of BlossomHill Therapeutics do insiders own?
Insiders, such as officers and directors, own about 12.71% of BLSM shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.